Salinomycin-Loaded Small-Molecule Nanoprodrugs Enhance Anticancer Activity in Hepatocellular Carcinoma

References

• Zhang Y, Guan DX, Shi J, et al. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. J Hepatol. 2013;59(6):1255–1263. doi:10.1016/j.jhep.2013.07.00923867314
   PubMed Web of Science ®Google Scholar
• Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest. 2013;123(5):1911–1918. doi:10.1172/JCI6602423635789
   PubMed Web of Science ®Google Scholar
• Yamashita T, Kaneko S. Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells. J Gastroenterol. 2014;49(7):1105–1110. doi:10.1007/s00535-014-0951-124647548
   PubMed Web of Science ®Google Scholar
• Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt–β-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007;67(22):10831–10839. doi:10.1158/0008-5472.CAN-07-090818006828
   PubMed Web of Science ®Google Scholar
• Wu CX, Wang XQ, Chok SH, et al. Blocking CDK1/PDK1/β-catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 2018;8(14):3737–3750. doi:10.7150/thno.2548730083256
   PubMed Web of Science ®Google Scholar
• Mendes LP, Sarisozen C, Luther E, Pan J, Torchilin VP. Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers. Drug Deliv. 2019;26(1):443–458. doi:10.1080/10717544.2019.157493530929529
   PubMed Web of Science ®Google Scholar
• Khan MW, Zhao P, Khan A, et al. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity. Int J Nanomedicine. 2019;14:3753–3771. doi:10.2147/IJN.S19665131239661
   PubMed Web of Science ®Google Scholar
• Wang HX, Xie HY, Wang JG, et al. Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy. Adv Funct Mater. 2015;25(31):4956–4965. doi:10.1002/adfm.201501953
   Web of Science ®Google Scholar
• Chen F, Zeng Y, Qi X, et al. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells. Nanomedicine. 2018;14:2115–2127.29898423
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645–659. doi:10.1016/j.cell.2009.06.03419682730
   PubMed Web of Science ®Google Scholar
• Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394(4):1098–1104. doi:10.1016/j.bbrc.2010.03.13820350531
   PubMed Web of Science ®Google Scholar
• Resham K, Patel PN, Thummuri D, et al. Preclinical drug metabolism and pharmacokinetics of salinomycin, a potential candidate for targeting human cancer stem cells. Chem Biol Interact. 2015;240:146–152. doi:10.1016/j.cbi.2015.08.00726282489
   PubMed Web of Science ®Google Scholar
• Mao X, Liu J, Gong Z, et al. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Nanomedicine. 2015;10(17):2677–2695. doi:10.2217/nnm.15.10626355733
   PubMed Web of Science ®Google Scholar
• Xie F, Zhang S, Liu J, et al. Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro. Nanomedicine. 2016;11(14):1831–1846. doi:10.2217/nnm-2016-012527391366
   PubMed Web of Science ®Google Scholar
• Wang Q, Wu P, Ren W, et al. Comparative studies of salinomycin-loaded nanoparticles prepared by nanoprecipitation and single emulsion method. Nanoscale Res Lett. 2014;9(1):351. doi:10.1186/1556-276X-9-35125147486
   PubMedGoogle Scholar
• Jin JL, Gong J, Yin TJ, et al. PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo. Eur J Pharmacol. 2011;654(1):17–25. doi:10.1016/j.ejphar.2010.12.00421184754
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Z, Wang L, et al. New generation nanomedicines constructed from self-assembling small-molecule prodrugs alleviate cancer drug toxicity. Cancer Res. 2017;77(24):6963–6974. doi:10.1158/0008-5472.CAN-17-098429055017
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207. doi:10.1016/S0065-2571(00)00013-311384745
   PubMedGoogle Scholar
• Mei L, Rao J, Liu Y, Li M, Zhang Z, He Q. Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes. J Control Release. 2018;292:67–77. doi:10.1016/j.jconrel.2018.04.05329723611
   PubMed Web of Science ®Google Scholar
• Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815–823. doi:10.1038/nnano.2011.16622020122
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv. 2013;4(4):421–423. doi:10.4155/tde.13.823557281
   PubMedGoogle Scholar
• Perry JL, Reuter KG, Luft JC, Pecot CV, Zamboni W, DeSimone JM. Mediating passive tumor accumulation through particle size, tumor type, and location. Nano Lett. 2017;17(5):2879–2886. doi:10.1021/acs.nanolett.7b0002128287740
   PubMed Web of Science ®Google Scholar
• Chen D, Wu M, Li Y, et al. Targeting BMI1(+) cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma. Cell Stem Cell. 2017;20(5):621–634 e6. doi:10.1016/j.stem.2017.02.00328285905
   PubMed Web of Science ®Google Scholar
• Dianat-Moghadam H, Heidarifard M, Jahanban-Esfahlan R, et al. Cancer stem cells-emanated therapy resistance: implications for liposomal drug delivery systems. J Control Release. 2018;288:62–83. doi:10.1016/j.jconrel.2018.08.04330184466
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–111. doi:10.1038/3510216711689955
   PubMed Web of Science ®Google Scholar
• McClements L, Annett S, Yakkundi A, et al. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer. 2019;19(1):351. doi:10.1186/s12885-019-5500-030975104
   PubMedGoogle Scholar
• Wang X, Cao Y, Zhang S, et al. Stem cell autocrine CXCL12/CXCR4 stimulates invasion and metastasis of esophageal cancer. Oncotarget. 2017;8(22):36149–36160. doi:10.18632/oncotarget.1525428193907
   PubMedGoogle Scholar
• Wang C, Shao L, Pan C, et al. Elevated level of mitochondrial reactive oxygen species via fatty acid β-oxidation in cancer stem cells promotes cancer metastasis by inducing epithelial–mesenchymal transition. Stem Cell Res Ther. 2019;10(1):175. doi:10.1186/s13287-019-1265-231196164
   PubMedGoogle Scholar
• Jang JW, Song Y, Kim SH, et al. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. Cancer Lett. 2017;389:1–10. doi:10.1016/j.canlet.2016.12.02328034805
   PubMed Web of Science ®Google Scholar
• Bai HY, Liao YJ, Cai MY, et al. Eukaryotic initiation factor 5A2 contributes to the maintenance of CD133(+) hepatocellular carcinoma cells via the c-Myc/microRNA-29b axis. Stem Cells. 2018;36(2):180–191. doi:10.1002/stem.273429119708
   PubMed Web of Science ®Google Scholar
• Tang H, Jin Y, Jin S, Tan Z, Peng Z, Kuang Y. Arsenite inhibits the function of CD133(+) CD13(+) liver cancer stem cells by reducing PML and Oct4 protein expression. Tumour Biol. 2016;37(10):14103–14115. doi:10.1007/s13277-016-5195-727517564
   PubMedGoogle Scholar
• Yang T, Chen Y, Zhao P, et al. Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules. Nanomedicine. 2018;14(7):2009–2021. doi:10.1016/j.nano.2018.05.01229842934
   PubMed Web of Science ®Google Scholar
• Wu R, Murali R, Kabe Y, et al. Baicalein targets GTPase-mediated autophagy to eliminate liver tumor-initiating stem cell-like cells resistant to mTORC1 inhibition. Hepatology. 2018;68(5):1726–1740. doi:10.1002/hep.3007129729190
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yan IK, Kogure T, Haga H, Patel T. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio. 2014;4:458–467. doi:10.1016/j.fob.2014.04.007
   PubMed Web of Science ®Google Scholar
• Fong ELS, Toh TB, Lin QXX, et al. Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer. Biomaterials. 2018;159:229–240. doi:10.1016/j.biomaterials.2017.12.02629353739
   PubMed Web of Science ®Google Scholar
• Coussy F, de Koning L, Lavigne M, et al. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. Int J Cancer. 2019. doi:10.1002/ijc.32266
   PubMed Web of Science ®Google Scholar
• Wang W, Iyer NG, Tay HT, et al. Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma. BMC Cancer. 2015;15:828. doi:10.1186/s12885-015-1814-826520397
   PubMed Web of Science ®Google Scholar
• Zhang X, Claerhout S, Prat A, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73(15):4885–4897. doi:10.1158/0008-5472.CAN-12-408123737486
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhao J, Pang Q, Wang A, Chen M, Wei X. An in vitro study on the effects of the combination of salinomycin with cisplatin on human gastric cancer cells. Mol Med Rep. 2017;16(2):1031–1038. doi:10.3892/mmr.2017.673128627601
   PubMed Web of Science ®Google Scholar
• Yu Z, Cheng H, Zhu H, et al. Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5. Braz J Med Biol Res. 2017;50(10):e6147. doi:10.1590/1414-431x2017614728832761
   PubMed Web of Science ®Google Scholar
• Sommer AK, Hermawan A, Mickler FM, et al. Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases. Oncotarget. 2016;7(31):50461–50476. doi:10.18632/oncotarget.1045927409163
   PubMedGoogle Scholar
• Zhu M, Chen S, Hua L, et al. Self-targeted salinomycin-loaded DSPE-PEG-methotrexate nanomicelles for targeting both head and neck squamous cell carcinoma cancer cells and cancer stem cells. Nanomedicine. 2017;12(4):295–315. doi:10.2217/nnm-2016-038228093940
   PubMed Web of Science ®Google Scholar
• Gong Z, Chen D, Xie F, et al. Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells. Nanomedicine. 2016;11(19):2565–2579. doi:10.2217/nnm-2016-013727647449
   PubMed Web of Science ®Google Scholar
• Zhang T, Huang P, Shi L, et al. Self-assembled nanoparticles of amphiphilic twin drug from floxuridine and bendamustine for cancer therapy. Mol Pharm. 2015;12(7):2328–2336. doi:10.1021/acs.molpharmaceut.5b0000525996874
   PubMedGoogle Scholar
• Liang X, Gao C, Cui L, Wang S, Wang J, Dai Z. Self-assembly of an amphiphilic janus camptothecin-floxuridine conjugate into liposome-like nanocapsules for more efficacious combination chemotherapy in cancer. Adv Mater. 2017;29(40):1703135. doi:10.1002/adma.201703135
   Web of Science ®Google Scholar
• Wang M, Xie F, Wen X, et al. Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells. Nanomedicine. 2017;12(9):1025–1042. doi:10.2217/nnm-2016-040828440698
   PubMed Web of Science ®Google Scholar
• Wang F, He L, Dai WQ, et al. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 2012;7(12):e50638. doi:10.1371/journal.pone.005063823284640
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liang C, Xue F, et al. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget. 2015;6(12):10350–10365. doi:10.18632/oncotarget.358525871400
   PubMedGoogle Scholar